Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5252W HIGH $15.94
Volume
27.84 K
Value Traded
82.17 K
Short % Float
0.38%
+8.92%Week
-3.93%1 Month
-80.63%3 Month
-79.17%6 Month
-100%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
28.95 M
EPS (TTM)
-2.53
P/E Ratio
-
Ent. Value
20.57 M
Total Shares
16.93 M
Float Shares
15.99 M
Insiders
5.56%
Institutions
0.20%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
RNAZ Catalyst Timeline
Dated clinical, regulatory and corporate events for TransCode Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for TransCode Therapeutics, Inc.
269Total events
6Upcoming
28Tier-1 (high impact)
2021 to 2039Coverage
Upcoming catalysts 2
Event history 50
▲Patent GrantedIP / Competition
IP Australia issues Notice of Acceptance for Patent Application No. 2019349817 'Compositions and Methods for Immune Checkpoint Inhibition'
cancer (colon, lung, breast, pancreatic, ovarian)source ↗
▲PublicationTTX-MC138Presentation
Publication of peer-reviewed article in Cancers on TTX-MC138 in preclinical model of breast cancer bone metastasis
breast cancer bone metastasissource ↗
◆R&D DayPresentation
R&D Webcast to provide strategic, scientific, and clinical program updates
▲Partnership / LicenseCorporate
Licensing of immuno-oncolytic portfolio from Unleash Immuno Oncolytics
▼Equity OfferingCorporate
Series C Preferred $20 million SEPA transaction with Yorkville Advisors
▲Trial InitiationTTX-MC138Trial
Phase 2a clinical trial of TTX-MC138 initiated
ctDNA-positive colorectal cancersource ↗
◆Enrollment UpdateTTX-MC138Trial
Phase 2a trial beginning enrollment
ctDNA-positive colorectal cancersource ↗
▲Trial InitiationTTX-MC138Trial
Initiation of Phase 2a clinical trial of TTX-MC138 in patients with ctDNA positive colorectal cancer
ctDNA positive colorectal cancersource ↗
▲Management ChangeCorporate
Appointment of Dr. Anna Moore as Chair of Scientific Advisory Board
▲Partnership / LicenseCorporate
TransCode secures exclusive worldwide license for UIO-524, UIO-525, UIO-526 from Unleash
solid tumors, muscle-invasive bladder cancersource ↗
●PublicationPresentation
Publication of manuscript on RIG-I agonist in Molecular Imaging and Biology
cancersource ↗
●IND SubmissionTTX-MC138IND
IND amendment submitted for Phase 2a trial of TTX-MC138 in colorectal cancer
colorectal cancersource ↗
▲Preclinical PoCTTX-MC138Preclinical
Publication of preclinical data showing TTX-MC138 delivery to GBM tumors and extended survival in murine models
glioblastoma multiforme (GBM)source ↗
◆Trial InitiationTTX-MC138Trial
Phase 2a dose-expansion trial planned to begin in first half of 2026
colorectal cancersource ↗
▲Partnership / LicenseCorporate
Collaboration with Quantum Leap Healthcare Collaborative to evaluate TTX-MC138 in PRE-I-SPY platform
◆Poster PresentationTTX-MC138Presentation
Preliminary data presented at ESMO Congress 2025
metastatic diseasesource ↗
◆Management ChangeCorporate
Philippe Calais appointed CEO; Tom Fitzgerald steps down as interim CEO but remains CFO
▲Management ChangeCorporate
Appointment of Dr. Phillip D. Zamore to Scientific Advisory Board
▲First Patient DosedTTX-MC138Trial
Third patient in Cohort 4 received initial dose of TTX-MC138
metastatic solid cancerssource ↗
▲Enrollment MilestoneTTX-MC138Trial
All cohorts enrolled at least three patients dosed with TTX-MC138
metastatic solid cancerssource ↗
▲Safety Data UpdateTTX-MC138Clinical Data
No dose limiting toxicities reported in any of the 15 patients
metastatic solid cancerssource ↗
▲PK PD DataTTX-MC138Clinical Data
Preliminary PK/PD data from Cohorts 1-3 show dose-response relationship and miR-10b target engagement
metastatic solid cancerssource ↗
◆Timing GuidancePresentation
Deadline to achieve $1.00 closing bid price to maintain Nasdaq listing
▼Reverse Stock SplitCorporate
Board approved 1-for-28 reverse stock split to meet Nasdaq minimum bid price
●Enrollment UpdateTTX-MC138Trial
13 patients enrolled, 2 in expanded enrollment
metastatic cancersource ↗
▲Safety Data UpdateTTX-MC138Clinical Data
No dose limiting toxicities reported in 13 patients
metastatic cancersource ↗
▲PK PD DataTTX-MC138Clinical Data
Preliminary PK/PD data from Cohorts 1-3 show dose-response and target engagement
metastatic cancersource ↗
◆Reverse Stock SplitCorporate
Special meeting to vote on reverse stock split to maintain Nasdaq listing
▲Quarterly UpdateTTX-MC138Corporate
TTX-MC138 Phase 1 trial well into fourth dosing cohort
cancersource ↗
▲First Patient DosedTTX-MC138Trial
First patient dosed in Cohort 4 of Phase 1 trial
metastatic solid cancerssource ↗
●Enrollment UpdateTTX-MC138Trial
Additional patients being evaluated for expanded enrollment in Cohort 3
metastatic solid cancerssource ↗
▲Safety Data UpdateTTX-MC138Clinical Data
No significant safety or dose limiting toxicities reported
metastatic solid cancerssource ↗
Past FDA Catalysts and PDUFA Decisions
How RNAZ actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | TTX-MC138 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F15 / 100
Pipeline Score
$3M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 98%
Micro Cap(rank 645 of 658)
Percentile Rank
TransCode Therapeutics, Inc. has significant pipeline risk (15/100), with $380M risk-adjusted pipeline value, led by TTX-MC138 in Advanced Solid Tumor (Phase 1), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TTX-MC138-NODAGA-Cu64 Small moleculeCompletedNCT05908773 | Advanced Solid Tumor | Phase 1 | COMPLETED | 1 | Sep 18, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every RNAZ program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TTX-MC138 Orphan | metastatic cancer | Phase 1a | 2026-06-03 | no dose-limiting toxicities, durable disease stabilization in metastatic patientsRead More | TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fitzgerald Thomas ADirector, Officer (Chief Financial Officer) | Buy | 49,350 56,318 held | $0.51 | 09/28/2023 |
Hedge Fund 13F Activity
Hedge Funds invested in RNAZ
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 0 % | 42.00 K | 84.01 K |
RNAZ Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How RNAZ ranks across every disease it competes in
Competitive Position is a premium feature
See how RNAZ ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialRNAZ News
RNAZ▲ +7.4%on this news
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
TransCode has reported ongoing positive results from its Phase 1a clinical trial of TTX-MC138, highlighting continued disease stabilization and an extended treatment duration. These findings suggest promising therapeutic potential for TTX-MC138 in treating the targeted condition. The trial's follow-up results contribute to the growing body of evidence supporting the drug's efficacy.
Read more →RNAZTransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
TransCode Therapeutics announced important advancements in its intellectual property, with a patent acceptance in Australia and a Notice of Allowance in Japan. These patents cover innovative RNA-based therapies aimed at cancer treatment. The developments enhance the company's ability to deliver targeted cancer therapies and strengthen its global market position.
Read more →RNAZTransCode Therapeutics Announces Leadership Transition
TransCode Therapeutics announced the retirement of CFO Tom Fitzgerald, effective immediately. John Tattory has been appointed as the Interim CFO, bringing over 25 years of financial experience. Fitzgerald played a crucial role in the company's growth and development, including its IPO and clinical program launches. Tattory's expertise is expected to guide the company through this transition.
Read more →RNAZTransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
TransCode Therapeutics announced a publication in Cancers demonstrating that its lead candidate, TTX-MC138, significantly improves survival in a preclinical model of breast cancer bone metastasis. The study highlights the therapeutic potential of inhibiting microRNA-10b, showing favorable tolerability and no systemic toxicity. These findings suggest broader applicability for TTX-MC138 in treating metastatic cancers.
Read more →RNAZThree Platforms, One Mission: Transforming Advanced Cancer Care NASDAQ: RNAZ Company Forward Looking Statement 2 Before you invest in the securities of TransCode Therapeutics, Inc. (“TransCode” or the  
TransCode Therapeutics (RNAZ) is focused on advancing cancer care through its innovative three-platform approach aimed at enhancing treatment for metastatic cancer. The company is prioritizing the clinical development of TTX-MC138, with several key catalysts anticipated in the upcoming 18 months, including trial enrollment milestones and data readouts. TransCode aims to leverage a balanced portfolio to drive innovation and potentially secure significant clinical advancements in the oncology sector.
Read more →RNAZ▼ -9.1%on this newsshared move
TransCode Therapeutics to Host R&D Webcast on June 18, 2026
TransCode Therapeutics will host a live R&D webcast on June 18, 2026, to discuss updates on its Phase 2a trial of TTX-MC138 for colorectal cancer. The event will cover the company's three-platform pipeline and investment strategies. Key speakers include prominent figures from the medical and scientific community.
Read more →RNAZTransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer
TransCode Therapeutics has successfully completed its Phase 1a clinical trial for TTX-MC138, demonstrating safety and durable disease stabilization in metastatic cancer patients. The trial met its primary endpoint with no dose-limiting toxicities. Following these promising results, the company plans to advance TTX-MC138 into Phase 2a development, focusing on ctDNA-positive colorectal cancer.
Read more →RNAZ▼ -5.6%on this news
TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer
TransCode Therapeutics has initiated a Phase 2a clinical trial for TTX-MC138, targeting patients with ctDNA positive colorectal cancer post-curative therapy. The trial aims to evaluate the drug's effectiveness in reducing cancer recurrence risk. Conducted in collaboration with Quantum Leap Healthcare, it will enroll up to 45 patients and is expected to provide valuable data on ctDNA testing.
Read more →RNAZTransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University
TransCode Therapeutics has appointed Dr. Anna Moore as Chair of its Scientific Advisory Board and signed a sponsored research agreement with Michigan State University. Dr. Moore, a co-founder of TransCode, will guide the company's research on RNA-based cancer therapies. The agreement aims to accelerate the development of TransCode's pipeline candidates, including TTX-MC138, in combination with other therapies.
Read more →RNAZTransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028
TransCode Therapeutics has entered into a financing agreement with an institutional investor for up to $20 million, which includes a pre-paid advance and a Standby Equity Purchase Agreement. This funding aims to support the ongoing Phase 2a trial of TTX-MC138, a candidate targeting metastatic cancers. The financing enhances the company's operational runway into late 2027 or early 2028.
Read more →RNAZTransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
TransCode Therapeutics has entered into a royalty-free license agreement with Unleash Immuno Oncolytics to develop three drug candidates, including UIO-524, aimed at treating muscle-invasive bladder cancer. This acquisition enhances TransCode's oncology pipeline and addresses significant unmet medical needs. The agreement involves a one-time payment in the form of preferred stock, representing a notable expansion for the company.
Read more →RNAZTransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development
TransCode Therapeutics announced the publication of a study on its RIG-I immunotherapeutic candidate, highlighting a novel approach that activates immune signaling in cancer cells while allowing for non-invasive imaging. The research, conducted in collaboration with Michigan State University, addresses challenges of off-target activation and delivery inefficiencies. The findings support further development of TransCode's TTX nanoparticle delivery platform in clinical settings.
Read more →RNAZ▲ +16.2%on this news
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138
TransCode Therapeutics has submitted an IND amendment for a Phase 2a trial of TTX-MC138, aimed at colorectal cancer patients. This trial, part of the PRE-I-SPY program, will enroll up to 45 patients with positive ctDNA markers. The study seeks to assess the drug's effectiveness in improving long-term cancer outcomes and is set to begin in the first half of 2026.
Read more →RNAZTransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
TransCode Therapeutics announced the publication of preclinical research validating the therapeutic potential of TTX-MC138 for glioblastoma multiforme (GBM). The study, published in the Journal of Functional Biomaterials, shows that TTX-MC138 can deliver antisense oligonucleotides effectively to tumors in murine models, leading to extended survival rates. These findings support the drug's advancement into further clinical trials aimed at treating aggressive GBM.
Read more →RNAZABCJ, LLC Reports and Financial Statements For the years ended
ABCJ, LLC has released its consolidated financial statements for the years ending December 31, 2024 and 2023, showcasing a decline in financial performance. The company reported a net loss of $16,351 for the year 2024, an increase from $11,515 in 2023. Additionally, the accumulated deficit grew to $193,090, further emphasizing the company's ongoing financial struggles. Despite these challenges, the members' equity saw a slight increase from $17,633 in 2023 to $17,782 in 2024.
Read more →RNAZTransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
TransCode Therapeutics has appointed Jack E. Stover to its Board of Directors, enhancing its leadership team. Stover, with over 30 years of experience in life sciences, will contribute to the Audit and Nominating Committees. His background in drug development and strategic growth is seen as a valuable asset as the company progresses in its RNA and immuno-oncology pipeline.
Read more →RNAZTransCode Expands Leadership with Appointment of Jack E. Stover to BOSTON, Dec 22, 2025- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment
TransCode Therapeutics has announced the appointment of Jack E. Stover to its Board of Directors, bringing over 30 years of leadership experience in life sciences. Stover will serve on the Audit and Nominating Committees, filling the position left by Dr. Magda Marquet. His expertise is expected to boost TransCode's pipeline in RNA and immuno-oncology as the company progresses its clinical initiatives.
Read more →RNAZ▲ +20.7%on this news
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode
TransCode Therapeutics and Quantum Leap Healthcare Collaborative have initiated a Phase 2a dose-expansion trial for TTX-MC138, targeting colorectal cancer patients at risk of recurrence. The trial will evaluate the drug's efficacy in patients who have shown a positive response to standard curative therapies but still show evidence of circulating tumor DNA. This initiative follows positive results from a Phase 1a trial, which established TTX-MC138's safety and potential clinical benefits. The trial aims to fill an unmet need in cancer treatment by addressing Minimal Residual Disease and aims to begin enrollment in the first half of 2026.
Read more →RNAZTransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
TransCode Therapeutics has appointed Dr. Michel Janicot as Senior Development Officer to enhance its oncology pipeline. Dr. Janicot, with over 35 years of experience, will initially work part-time and focus on advancing the company's lead programs. His expertise in RNA biology and oncology strategy is expected to be crucial for the company's growth.
Read more →RNAZ▲ +5.6%on this news
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
TransCode Therapeutics has completed its Phase 1a trial for TTX-MC138, an inhibitor of microRNA-10b, successfully meeting safety endpoints and establishing a recommended Phase 2 dose. The trial involved 16 patients, with no significant safety events reported. Positive pharmacodynamic effects were observed, leading to plans for a Phase 2a trial to further evaluate efficacy in metastatic diseases.
Read more →About TransCode Therapeutics, Inc.
Headquarters6 LIBERTY SQUARE, BOSTON, MA, 02109
BIOPHARMAWATCH ELITE PLUS
Trade the next RNAZ catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime